ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > RON

RON

概要

Name:Macrophage-stimulating protein receptor
Target Synonym:EC 2.7.10.1,Protein-Tyrosine Kinase 8,RON,Macrophage-Stimulating Protein Receptor,SEA,S13 Erythroblastosis Oncogene Homolog,S13 Erythroblastosis (Avian) Oncogene Homolog,Macrophage Stimulating 1 Receptor,PTK8 Protein Tyrosine Kinase 8,S13 Avian Erythroblastosis Oncogene Homolog,MST1R,NPCA3,CD136 Antigen,C-Met-Related Tyrosine Kinase,CD136,CDw136,PTK8,P185-Ron,EC:2.7.10.1,MSP Receptor,EC 2.7.10
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
RON-H52H9 Human Human RON / MSPR Protein, His Tag (MALS verified)
RON-H52H9-structure
RON-H52H9-sds
ACRO Quality

生物活性データの一部

RON-H52H9-MALS-HPLC
RON MALS images

The purity of Human RON, His Tag (Cat. No. RON-H52H9) is more than 90% and the molecular weight of this protein is around 60-80 kDa verified by SEC-MALS.

Synonym Name

CD136 antigen,CD136,CDw136c-met-related tyrosine kinase,EC 2.7.10,EC 2.7.10.1,macrophage stimulating 1 receptor (c-met-related tyrosine kinase),MSP R,MSP receptor,MSPR,MST1R,p185-Ron,Protein-tyrosine kinase 8,PTK8 protein tyrosine kinase 8,PTK8,Ron,RONmac

Background

Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to MST1 ligand. Regulates many physiological processes including cell survival, migration and differentiation. Ligand binding at the cell surface induces autophosphorylation of RON on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1 or the adapter GAB1. Recruitment of these downstream effectors by RON leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. RON signaling activates the wound healing response by promoting epithelial cell migration, proliferation as well as survival at the wound site. Plays also a role in the innate immune response by regulating the migration and phagocytic activity of macrophages. Alternatively, RON can also promote signals such as cell migration and proliferation in response to growth factors other than MST1 ligand.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Crizotinib PF-1066; PF-2341066; PF-02341066; PF-002341066 Approved Pfizer Inc 赛可瑞, Xalkori United States Carcinoma, Non-Small-Cell Lung Pf Prism Cv 2011-08-26 Urethral Neoplasms; Neurilemmoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Granuloma, Plasma Cell; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lung Neoplasms; Lymphoma; Ureteral Neoplasms; Neuroblastoma; Solid tumours; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Uveal melanoma; Myofibroma; Multiple Myeloma; Neurofibromatosis 2; Kidney Diseases; Small Cell Lung Carcinoma; Neoplasms; Hematologic Neoplasms Details
Crizotinib PF-1066; PF-2341066; PF-02341066; PF-002341066 Approved Pfizer Inc 赛可瑞, Xalkori United States Carcinoma, Non-Small-Cell Lung Pf Prism Cv 2011-08-26 Urethral Neoplasms; Neurilemmoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Granuloma, Plasma Cell; Endometrial Neoplasms; Lymphoma, Large-Cell, Anaplastic; Lung Neoplasms; Lymphoma; Ureteral Neoplasms; Neuroblastoma; Solid tumours; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Uveal melanoma; Myofibroma; Multiple Myeloma; Neurofibromatosis 2; Kidney Diseases; Small Cell Lung Carcinoma; Neoplasms; Hematologic Neoplasms Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 2 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Do-2 Do-2 Phase 1 Clinical DeuterOncology NV Lung Neoplasms Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase 2 Clinical Hec Pharm Co Ltd Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
Do-2 Do-2 Phase 1 Clinical DeuterOncology NV Lung Neoplasms Details

This web search service is supported by Google Inc.

totopphone